Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTISGCA)

• DTT Name: Toll-like receptor 4 (TLR4) DTT Info
• Gene Name: TLR4

Molecule-Related Drug & Molecule List

9 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MPL-containing Pollinex allergy desensitization vaccine	DMXSDJU	Allergy	4A80-4A85	Preregistration	[1]
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[2]
ERITORAN	DMKQZ0L	Sepsis	1G40-1G41	Phase 3	[3]
Resatorvid	DMFMWYC	Sepsis	1G40-1G41	Phase 3	[4]
G100	DMKHNXA	Non-hodgkin lymphoma	2B33.5	Phase 2	[5]
CRX-675	DMHDSYF	Hepatitis virus infection	1E50-1E51	Phase 1	[6]
GSK1795091	DMC6QE4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
NI-0101	DM31FOP	Autoimmune diabetes	5A10	Phase 1	[6]
OM-174	DM2THBX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CS-4771	DMVDLT4	Sepsis	1G40-1G41	Discontinued in Phase 1	[8]
LZ-8	DM679IY	Autoimmune diabetes	5A10	Terminated	[6]

10 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3-Hydroxy-Myristic Acid	DMFJLWO	Discovery agent	N.A.	Investigative	[9]
6-(2-aminophenoxy)benzo[d]isothiazol-3-amine	DMXFRW9	Discovery agent	N.A.	Investigative	[3]
AS04	DMAWJPE	Discovery agent	N.A.	Investigative	[6]
CRX-526	DMW61UK	Discovery agent	N.A.	Investigative	[10]
Fibronectin extra domain A	DMUX702	Discovery agent	N.A.	Investigative	[6]
Lauric Acid	DM9C8KQ	Discovery agent	N.A.	Investigative	[9]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[11]
OM-197-MP-AC	DME8RNV	Solid tumour/cancer	2A00-2F9Z	Investigative	[6]
OM-294-DP	DML5AWQ	Solid tumour/cancer	2A00-2F9Z	Investigative	[6]
TriMixDC	DML3OYH	Melanoma	2C30	Investigative	[12]

References

• [1] Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
• [2] Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
• [3] Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
• [4] Clinical pipeline report, company report or official report of Takeda (2009).
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
• [7] Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
• [8] Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013
• [9] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [10] The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4.
• [11] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [12] Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.